Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 4 · 57.1%GRADE not reported 0 · 0%Very low 3 · 42.9%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether olokizumab changes clinical improvement D28b compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.1 [0.96, 1.24]
1 study · 248 participants
Very low

Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

WHO progression score (level 7 or above) D28 ‐ not reported · people with mild/moderate/severe/critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether olokizumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.5 [0.55, 4.09]
1 study · 248 participants
Very low

All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adverse events ‐ not reported · people with mild/moderate/severe/critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether olokizumab changes serious adverse events ( compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.25 [0.51, 3.06]
1 study · 248 participants
Very low